Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
September 05 2023 - 8:00AM
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage
precision oncology company developing MasterKey therapies that
target families of oncogenic mutations in patients with genetically
defined cancers, today announced that company management will
participate in three upcoming investor conferences:
- The 2023 Wells Fargo
Healthcare Conference on Wednesday, September 6, 2023, in Boston,
MA.
- The Morgan Stanley
21st Annual Global Healthcare Conference on Monday, September 11,
2023. Black Diamond President and Chief Executive Officer, David M.
Epstein, Ph.D. will participate in a fireside chat at 3:35 p.m. ET
in New York, NY.
- The H.C. Wainwright
25th Annual Global Investment Conference on Tuesday, September 12,
2023. Black Diamond Chief Business Officer and Chief Financial
Officer, Fang Ni, Pharm.D. will present at 11:00 a.m. ET in New
York, NY.
A live webcast of the Morgan Stanley fireside chat and H.C.
Wainwright presentation can be accessed by visiting the investors
relations section of the Company’s website at:
www.blackdiamondtherapeutics.com. A replay of the webcast will also
be available and archived for 90 days following the event.
About Black Diamond
Black Diamond Therapeutics is a clinical-stage precision
oncology medicine company focused on the development of MasterKey
therapies that target families of oncogenic mutations in clinically
validated targets. Black Diamond leverages a deep understanding of
cancer genetics and onco-protein structure and function, to
discover and develop innovative MasterKey therapies. The Company’s
MasterKey therapies are designed to overcome resistance, minimize
on-target, wild-type mediated toxicities, and be brain penetrant to
address significant unmet medical needs of patients with
genetically defined cancers. The Company is advancing a robust
pipeline with lead clinical-stage program BDTX-1535, targeting
MasterKey mutations in both EGFR mutant-positive non-small cell
lung cancer (NSCLC) and in glioblastoma multiforme (GBM), and
BDTX-4933, a program targeting RAF MasterKey mutations in solid
tumors, as well as discovery-stage research programs. The Company’s
proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery
engine, is designed to allow Black Diamond to analyze
population-level genetic sequencing tumor data and validate
MasterKey mutations.
Contact:Julie Seidel, Stern Investor
Relations(212) 362-1200investors@bdtx.commedia@bdtx.com
Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From Apr 2024 to May 2024
Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From May 2023 to May 2024